Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Beam Therapeutics Inc. (BEAM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
42.51+0.94 (+2.26%)
At close: 04:00PM EDT
43.00 +0.49 (+1.15%)
After hours: 07:55PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close41.57
Open42.65
Bid40.17 x 800
Ask43.88 x 1000
Day's Range39.73 - 43.83
52 Week Range27.77 - 138.52
Volume2,415,741
Avg. Volume1,358,724
Market Cap2.987B
Beta (5Y Monthly)1.60
PE Ratio (TTM)N/A
EPS (TTM)-3.59
Earnings DateAug 08, 2022 - Aug 12, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est89.55
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BEAM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Beam Therapeutics Inc.
    Analyst Report: CRISPR Therapeutics AGCRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR’s most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
    Rating
    Fair Value
    Economic Moat
    10 days agoMorningstar
View more
Advertisement
Advertisement